Febuxostat
Brand names: Febuxostat, Uloric
At a glance
- Medicare prescriptions, 2024
- 161,477
- Medicare drug cost
- $16.1M
- Average cost per prescription
- $99.72
- Clinicians who prescribed it
- 7,754
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.
From the FDA-approved prescribing information (label dated December 2025). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: CARDIOVASCULAR DEATH Gout patients with established cardiovascular (CV) disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study. Consider the risks and benefits of ULORIC when deciding to prescribe or continue patients on ULORIC. ULORIC should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. WARNING: CARDIOVASCULAR DEATH See full prescribing information for complete boxed warning. Gout patients with established cardiovascular (CV) disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study. Consider the risks and benefits of ULORIC when deciding to prescribe or continue patients on ULORIC. ULORIC should…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Internal Medicine 24.4%
- Family Medicine 22.7%
- Rheumatology 17.9%
- Nephrology (Kidney) 15.7%
- Nurse Practitioners 9.5%
- Physician Assistants 4.1%
- Geriatric Medicine 1.1%
- General Practice 0.9%
- Cardiology 0.8%
- Podiatrists 0.8%
- Hospitalist 0.2%
- Hematology & Oncology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 41% from 2019 to 2024.
Biggest change by state since 2019
- Washington −27%
- Maryland −27%
- Minnesota −28%
- Michigan −30%
- Wisconsin −32%
- Mississippi (smallest change) −54%
- Oklahoma (smallest change) −52%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Hec Pharm USA Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | white round tablet, 9 mm | C33 |
| 80 mg | white capsule, 14 mm | C32 |
Novadoz Pharmaceuticals LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | green round tablet, 9 mm | 40 F |
| 80 mg | yellow oval tablet, 17 mm | 80 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | white oval tablet, 13 mm | 401 |
Solco Healthcare US LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | green round tablet, 9 mm | 284 S |
| 80 mg | green oval tablet, 16 mm | 296 S |
Takeda Pharmaceuticals America, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | green round tablet, 9 mm | TAP 40 |
| 80 mg | green tear tablet, 14 mm | TAP 80 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
3 recalls since 2020
- Mar 2024 · Sun Pharmaceutical Industries Inc · Class II
CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment. - Jan 2024 · Amerisource Health Services LLC · Class II
CGMP Deviations - Jan 2024 · Sun Pharmaceutical Industries Inc · Class II
CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.